Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-Grown tumor models could match patients to the right cancer drug

NCT ID NCT07820566

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers at University Hospital, Strasbourg, are developing 3D tumor models grown from patient tissue to study kidney, bladder, and prostate cancers. The study collects tumor samples and a small blood sample from about 100 adults with these cancers. Scientists use the blood to isolate immune cells and mix them into the tumor models, aiming to recreate a more realistic tumor environment. The goal is to see whether these models can predict how a patient's cancer responds to treatment, which could support personalized medicine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a laboratory-grown 3D tumor model made from a patient's own tumor cells and immune cells
What this could lead to
If it works, doctors could one day test cancer drugs on a patient's own tumor cells in the lab before choosing a treatment, potentially sparing patients from ineffective therapies.
What could go wrong
Growing tumor cells outside the body is difficult, and many models fail to survive or match how a real tumor behaves. This early-stage laboratory study may not produce a reliable model, and any treatment predictions would still need years of testing in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Male or female subject (≥18 years old); * Diagnosed with kidney cancer, prostate cancer, or bladder cancer; * whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677)

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria: * Criteria common to all patients: * Male or female subject (≥18 years old); * Diagnosed with kidney cancer, prostate cancer, or bladder cancer; * whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677); * affiliated with a social security health insurance scheme or beneficiary of such a scheme; * agreeing to participate in the 3DBlood study. * Specific criteria for patients with renal cell carcinoma (RCC): * Extended nephrectomy (EN) (larger tumor, closer to the sinus; therefore at greater risk of metastasis): with a cavo, cavectomy (neoplastic thrombus in the vena cava), or renal vein bud, or lymph node dissection, or with adrenalectomy (often for tumors, therefore possible metastases). Or \- Partial nephrectomy (PN): with tumors at stage T2 or T3a) Exclusion Criteria: * Patient refusal to participate in the study; * Inability to provide the subject with informed consent (subject in an emergency situation, difficulties in understanding the subject, etc.); * Patient under legal protection, guardianship, or conservatorship; * Patient currently participating in a therapeutic clinical trial (i.e., gene therapy or other).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer prostate cancer urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer Kidney cancers Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de Chirurgie Urologique _ Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.